Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

By Goodin Douglas S.   Biermann Louis D.   Bohlega Saeed   Boiko Alexey   Chofflon Michel   Gebeily Souheil   Gouider Riadh   Havrdova Eva   Jakab Gabor   Karabudak Rana   Karussis Dimitrios   Miller Ariel   Pakdaman Hossein   Selmaj Krzysztof   Sharief Mohammad    

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2823-2832

Informa Healthcare

Access to resources Recommend Favorite

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

By Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 869-877

Informa Healthcare

Access to resources Recommend Favorite

Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

By Cascione Mark  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 859-865

Informa Healthcare

Access to resources Recommend Favorite

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite